You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
EVALUATION OF THE EFFICACY AND SAFETY FOR CHRONIC HEPATITIS C TREATED WITH ELBASVIR/GRAZOPREVIR
- At: AbuDhabi (United Arab Emirates) (2019)
- Type: Poster
- Poster code: POS-HPS-027
- By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Pharmacy, China Taiwan)
- Co-author(s): Tzu-Cheng Tsai: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
Hui-Yu Chen: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
Shin-Tarng Deng: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
Chao-Wei Hsu: Gastroenterology and Hepatology, Chang Gung Memorial Hospital, China Taiwan - Abstract:
Background
Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed-dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection.Methods
This is a retrospective observational study. Patients were recruited who had received EBR/GZR for chronic HCV GT 1 between June 2017 and April 2018. Patients’ age, sex,.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026